#Israel #CollPlant #rhCollagen #Rehovot #VergenixSTR

CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

CollPlant Biotechnologies, a prominent player in regenerative and aesthetic medicine, is making strides in expanding its market presence by launching the distribution of its innovative product, Vergenix™ STR, across Europe and Asia. This strategic move marks a turning point for the company, which leverages its proprietary rhCollagen technology in its offerings.

The Vergenix™ STR Product

VergenixSTR is designed specifically for the treatment of tendinopathy, a condition that affects tendons and can lead to pain and dysfunction. It’s particularly effective for common tendon injuries, including those seen in tennis elbow, rotator cuff injuries, patellar tendinosis, and Achilles tendon injuries. The unique formulation of VergenixSTR creates a gel-like matrix that facilitates the sustained release of essential growth factors at the site of injury, thereby enhancing the healing process.

Recently, CollPlant secured distribution agreements with partners based in the Netherlands, Turkey, and India. This will enable the sale of VergenixSTR in multiple territories including the Netherlands, Belgium, Luxembourg (collectively known as Benelux), as well as Spain, India, and Turkey. The initial shipment to the distributor in Benelux was completed in February 2025, demonstrating a proactive approach to market entry.

Strategic Benefits and Market Potential

Yehiel Tal, the CEO of CollPlant, expressed enthusiasm about the distribution expansion, pointing out the extensive market potential for VergenixSTR in the European and Asia-Pacific regions. His comments reflect the belief that the product stands out due to its unique mechanism of action—delivering a gel matrix that not only supports growth factor release but also promotes optimal healing conditions directly at the injury site.

The new partnerships are particularly promising as the distributors in Turkey and India finalize their compliance with local regulations, aiming to begin sales within the year. The expertise of these distributors in medical devices, particularly orthopedics, is a valuable asset that CollPlant hopes will enhance its market penetration and brand recognition across the new territories.

The Technology Behind VergenixSTR

VergenixSTR combines cross-linked rhCollagen with Platelet-Rich Plasma (PRP), a treatment known for its high concentration of platelets that play a crucial role in the healing process. By utilizing this technology, VergenixSTR serves as a structural scaffold that supports cell growth and the gradual release of growth factors essential for tissue repair. It not only acts as a temporary reservoir for PRP at the tendon injury site but also has the ability to activate the platelets, facilitating a controlled release of bioactive factors that encourage healing.

As part of its growth strategy, CollPlant is also exploring other opportunities to further widen its distribution network for VergenixSTR beyond the current markets, enhancing its global footprint in the regenerative medicine sector.

Looking Ahead

As the year progresses, CollPlant is poised to take significant steps in not just expanding its distribution but also potentially diversifying its product offerings based on the robust platform of rhCollagen technology. The collaboration with Allergan, focused on dermal and soft tissue fillers, further exemplifies CollPlant's commitment to innovation in aesthetic medicine.

The proactive approach in securing partnerships and establishing distribution channels reflects CollPlant’s ambition to be at the forefront of regenerative medicine. For healthcare providers and patients alike, the availability of VergenixSTR could represent a transformative treatment option for tendon injuries, potentially offering improved healing outcomes compared to traditional therapies.

For more details on CollPlant’s initiatives and product offerings, visit their official website at CollPlant.